SL Science Holding Limited - (SLBT) closed at $1.20 on October 30, 2026, up 2.6% from the previous close, on volume of 26,606 shares (30-day average 62,266).
Data as of October 30, 2026.
SL Science Holding Limited Reports First Half 2026 Financial Results
Globe Newswire (Mon, 26-Oct 4:15 PM ET)
Globe Newswire (Thu, 24-Sep 8:00 AM ET)
Globe Newswire (Wed, 2-Sep 4:10 PM ET)
Globe Newswire (Thu, 27-Aug 8:00 AM ET)
Globe Newswire (Tue, 11-Aug 8:00 AM ET)
SL Science Highlights Strategic Shift and Major Pipeline Progress Amid Wider Losses in FY 2025
Market Chameleon (Mon, 22-Jun 3:06 AM ET)
Market Chameleon (Wed, 17-Jun 3:05 AM ET)
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
SL Science Holding Limited - trades on the NASDAQ stock market under the symbol SLBT.
As of October 30, 2026, SLBT stock price climbed to $1.20 with 26,606 million shares trading.
SLBT has a beta of 5.86, meaning it tends to be more sensitive to market movements. SLBT has a correlation of 0.18 to the broad based SPY ETF.
SLBT has a market cap of $672.91 million. This is considered a Small Cap stock.
SLBT support price is $1.08 and resistance is $1.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLBT shares will trade within this expected range on the day.
